What is post-COVID condition (long COVID)?

Post-COVID condition — widely called Long COVID — occurs when symptoms from COVID-19 persist or develop 3 months after the initial infection and last for at least 2 months without an alternative explanation. It is not a single condition but a constellation of symptoms affecting multiple organ systems. The most common manifestations: profound fatigue, post-exertional malaise (worsening after effort), cognitive impairment ("brain fog"), breathlessness, palpitations, pain, and sleep disturbance. An estimated 65 million people globally are living with post-COVID condition.

Risk factors for developing post-COVID: women are disproportionately affected (approximately 2:1 female predominance); severity of acute COVID (though many people with mild acute illness develop post-COVID); unvaccinated individuals; people with pre-existing health conditions; and — notably — asthma, anxiety/depression, and obesity are associated with higher risk. Age is not a simple predictor — young adults can develop severe post-COVID. Omicron variants appear to cause less post-COVID than Delta, but the huge number of Omicron infections means the absolute burden remains very large.

What are the main symptoms?

Post-COVID condition affects virtually every body system: Neurological: brain fog (most disabling — difficulty concentrating, word-finding, memory); headache; sleep disturbance; autonomic dysfunction (POTS — postural tachycardia syndrome — dizziness on standing); peripheral neuropathy. Respiratory: breathlessness; cough; reduced exercise capacity. Cardiovascular: palpitations; chest pain; myocarditis sequelae. Musculoskeletal: fatigue; muscle aches; joint pain. Gastrointestinal: nausea; diarrhoea; gut dysbiosis. Mental health: depression; anxiety; PTSD. Immune: post-exertional malaise — the cardinal symptom.

What causes long COVID?

Multiple mechanisms are likely active simultaneously and may vary between individuals: (1) Viral persistence: SARS-CoV-2 RNA/antigens persist in gut, lymph nodes and potentially CNS — driving chronic immune activation; (2) Immune dysregulation: autoantibodies, elevated cytokines, exhausted T-cells; (3) Reactivation of latent viruses: EBV reactivation is associated with post-COVID severity; (4) Gut microbiome disruption: COVID-19 alters the microbiome with persistent dysbiosis; (5) Endothelial dysfunction and microclots; (6) Mitochondrial dysfunction — impairing cellular energy production.

Does vaccination prevent long COVID?

Vaccination reduces the risk of developing post-COVID condition — most studies show approximately 30-50% risk reduction with primary COVID-19 vaccination in preventing long COVID after a breakthrough infection. Booster doses may provide additional protection. Early antiviral treatment (Paxlovid — nirmatrelvir/ritonavir within 5 days of symptom onset) may also reduce long COVID risk by shortening viral replication — clinical trials are ongoing.

How is long COVID managed?

No pharmacological treatment is specifically approved. Management principles: pacing and energy management — crucial for PEM (avoiding boom-bust activity cycles; heart rate monitoring to stay below anaerobic threshold); multidisciplinary post-COVID clinic approach (cardiologist, neurologist, pulmonologist, rehabilitation specialist, psychologist); treatment of specific complications (e.g., anticoagulation for POTS; melatonin/CBT for sleep; cognitive rehabilitation for brain fog); and mental health support. Research is actively investigating: low-dose naltrexone; anticoagulants; antivirals; immune-modulating agents.

Is long COVID the same as ME/CFS?

Post-COVID condition and ME/CFS share significant features — particularly post-exertional malaise (the hallmark of both). Approximately 50% of people with post-COVID at 12 months may meet ME/CFS diagnostic criteria (International Consensus Criteria). This has been transformative for ME/CFS — the COVID pandemic has brought enormous attention and research funding to a condition that had been dismissed for decades. However, some post-COVID manifestations (e.g., cardiac involvement, specific immune patterns) may be distinct from ME/CFS, and not all post-COVID evolves into ME/CFS.

How does GMJ News cover long COVID?

GMJ News covers WHO post-COVID definition, global burden estimates, mechanism research updates, vaccination and Paxlovid protection evidence, pacing guidance, and multidisciplinary clinic models. Long COVID represents a major new chronic disease burden directly relevant to PHIG's public health research agenda and the Georgian Medical Journal.

Home › Topics › Post-COVID Condition (Long COVID)

Post-COVID Condition (Long COVID)

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Post-COVID condition (commonly called Long COVID) — defined by WHO as symptoms occurring usually 3 months from onset of COVID-19, lasting at least 2 months and not explained by an alternative diagnosis — affects an estimated 10-20% of people who survive COVID-19 infection, equating to approximately 65 million people globally with persistent disabling symptoms (WHO 2021). Characteristic symptoms include profound fatigue, post-exertional malaise (worsening after physical or cognitive effort), cognitive impairment (“brain fog”), breathlessness, palpitations and sleep disturbance. The pathophysiology remains incompletely understood — with viral persistence, immune dysregulation, microbiome disruption, endothelial dysfunction and reactivation of latent herpesviruses all implicated.

Key messages

65 million people globally — WHO definition

Post-COVID condition affects an estimated 10-20% of COVID-19 survivors — approximately 65 million people globally — defined by WHO as symptoms occurring 3 months from COVID-19 onset, lasting ≥2 months and not explained by an alternative diagnosis.

Fatigue and brain fog dominate

The most common symptoms: post-exertional malaise (PEM — worsening after physical or cognitive effort); profound fatigue; cognitive impairment ("brain fog" — difficulty concentrating, memory problems); breathlessness; and palpitations.

Vaccination reduces but does not eliminate risk

COVID-19 vaccination reduces the risk of developing post-COVID condition — estimates range from 30-50% reduction with primary vaccination. Paxlovid (nirmatrelvir + ritonavir) early treatment may also reduce risk.

Mechanisms remain incompletely understood

Leading hypotheses: viral persistence (SARS-CoV-2 RNA/antigen in gut, lymph nodes); immune dysregulation (autoantibodies, T-cell activation); microbiome disruption; endothelial injury; mitochondrial dysfunction; reactivation of EBV and other latent herpesviruses.

ME/CFS overlap

Post-COVID condition shares significant overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) — particularly post-exertional malaise, which is the defining feature. Pacing (energy management) is essential; "graded exercise therapy" (GET) can worsen PEM.

No approved specific treatment

No pharmacological treatment is specifically approved for post-COVID condition. Management: pacing and energy management; treatment of specific organ complications; rehabilitation; mental health support. Clinical trials of numerous agents are ongoing.

Key statistics

~65M

estimated people globally with post-COVID condition

WHO/Lancet 2022

10-20%

of COVID survivors develop persistent symptoms

WHO

3 months

from COVID onset for WHO post-COVID definition

WHO Oct 2021

30-50%

reduction in post-COVID risk with vaccination

WHO/research

200+

documented post-COVID symptoms across body systems

WHO/Lancet

Oct 2021

year WHO published post-COVID condition definition (Delphi consensus)

WHO

Most common post-COVID symptoms — frequency in studies (%) — WHO/Lancet

Source: WHO/Lancet 2022 systematic review. Fatigue, brain fog and breathlessness dominate.

Glossary of key terms

WHO post-COVID definition
WHO Oct 2021Occurs in individuals with probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19, with symptoms that last at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms: fatigue, shortness of breath, cognitive dysfunction; generally have an impact on everyday functioning.

Post-exertional malaise (PEM)
WHO/ME/CFSA hallmark symptom of post-COVID condition (and ME/CFS) — the worsening of symptoms (fatigue, cognitive impairment, pain, breathlessness) following physical or cognitive effort, beyond what would be expected, and often with delayed onset (hours to days after exertion). PEM indicates possible mitochondrial dysfunction or immune activation on exertion.

ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome)
WHO/ICD-11A serious, chronic, complex multisystem disease — now recognised in ICD-11. Post-COVID condition commonly evolves into or overlaps with ME/CFS (approximately 50% of those with post-COVID at 12 months may meet ME/CFS criteria). The defining feature of ME/CFS is PEM. Graded exercise therapy (GET) — historically used for ME/CFS — is now recognised as potentially harmful if PEM is present.

Microclots (fibrinogen amyloid microclots)
ResearchA hypothesis gaining research support: SARS-CoV-2 spike protein triggers fibrinogen misfolding into amyloid-like microclots in the bloodstream that resist normal fibrinolysis — potentially obstructing microvascular blood flow and contributing to fatigue, cognitive impairment and organ dysfunction. A research focus for potential antiplatelet/anticoagulant interventions.

Viral persistence
ResearchEvidence that SARS-CoV-2 RNA and antigens can persist in gut tissue, lymph nodes and potentially other sites for months after acute infection — potentially acting as a reservoir for ongoing immune activation and symptom generation. A leading mechanism hypothesis with clinical trial implications (antivirals for post-COVID).

Pacing (activity management)
WHO/ME/CFS managementThe primary behavioural intervention for post-COVID with PEM — staying within individual energy limits ("energy envelope") to prevent boom-bust cycles of activity and crash. Heart rate monitoring (keeping HR below anaerobic threshold) is one strategy. Avoidance of overexertion is essential.